,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['in-person']
first in-person #asco22 with such an impactful plenary session marked by db04 results. it s exciting to see history being made. 
3rd year MedOnc fellow, São Paulo, Brazil.